MedTrace Logo

Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2)

NCT04800224 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-05-13

No results posted yet for this study

Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes challenging immune and inflammatory phenomena. Though various therapeutic possibilities have been tested against coronavirus disease 2019 (COVID-19), the most adequate treatment has not yet been established. Among candidate adjunct treatment options, propolis, produced by honey bees from bioactive plant exudates, has shown potential against viral targets and has demonstrated immunoregulatory properties.

Conditions

Interventions

DRUG

Standardized Brazilian Green Propolis Extract

900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.

DRUG

Placebo

900mg/day of Placebo for 10 days.

Sponsors & Collaborators

  • Apis Flora Industrial e Comercial Ltda

    collaborator UNKNOWN

  • D'Or Institute for Research and Education

    lead OTHER

Principal Investigators

  • Marcelo Silveira, MD, PhD · D'Or Institute for Research and Education (IDOR)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-12
Primary Completion
2021-07-30
Completion
2021-07-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04800224 on ClinicalTrials.gov